Allosteric modulation company Addex Therapeutics Ltd announced that it has launched a CHF 40 m capital increase with commitments in place from several world-leading healthcare investors,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
